The Committee for Medicinal Products for Human Use has recommended marketing authorisation for Kostaive, a self-replicating mRNA (“saRNA”) injection developed by Arcturus Therapeutics.  The final decision for regulatory approval now rests with the European Commission.

The European Commission must reject authorisation for these dangerous saRNA (replicon) vaccines.

Here’s a visual representation of how these dangerous genetic shots work:

Life Science Animation: Circular and Self-Amplifying RNA Explained | GenScript Mode of Action, 16 May 2024

Japan had already approved these injections last year. In November 2023, Japan’s Ministry of Health, Labor and Welfare (MHLW) fully approved CSL and Arcturus Therapeutics’ replicon shot, Kostaive ARCT-154. Despite enormous safety concerns, Japan’s MHLW approved the updated booster shot in September 2024 to target the JN.1 lineage of Omicron subvariants.

During the clinical trials for Kostaivefive deaths were reported among participants in the phase 3b study. Across study phases 1, 2, and 3a combined, 90% of injected participants experienced adverse events, with 74.5% reporting systemic reactions and 15.2% requiring medical attention after the first dose. Notably, many of the study authors are full-time employees of Arcturus Therapeutics, raising concerns about bias in their conclusions.

It’s become abundantly clear that the pharmaceutical industry and captured regulatory agencies have zero regard for the massive safety concerns of undefined synthetic mRNA replication resulting in uncontrolled toxic antigen production. These experimental injections must not receive further regulatory approval for humans or animals if we are to prevent another public health disaster. All self-amplifying mRNA injections currently available for humans and animals should be immediately withdrawn until comprehensive, long-term safety studies are conducted.Attack of the Replicons, Courageous Discourse, 7 November 2024

Read More – European Committee gives green light to use self-replicating vaccines on citizens of EU countries [Article from 15/12/24]

Leave a Reply

Your email address will not be published. Required fields are marked *